Literature DB >> 14740074

Atherosclerosis in type 2 diabetes mellitus: the role of insulin resistance.

Karol E Watson1, Anne L Peters Harmel, Gary Matson.   

Abstract

Type 2 diabetes mellitus is associated with a marked increase in the risk of atherosclerotic diseases, including coronary heart disease, peripheral arterial disease, and cerebrovascular disease. Insulin resistance is a key factor in the pathogenesis of type 2 diabetes mellitus. Insulin resistance and its attendant metabolic abnormalities may cause much of the increased cardiovascular risk of type 2 diabetes mellitus. Among the abnormalities associated with insulin resistance are dyslipidemia, hypertension, systemic inflammation, and a prothrombotic state. This review discusses the role that each of these disorders plays in the cardiovascular risk of type 2 diabetes mellitus.

Entities:  

Mesh：

Year:  2003        PMID： 14740074     DOI： 10.1177/107424840300800402

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol Ther        ISSN： 1074-2484            Impact factor:   2.457


  13 in total

Review 1.  MicroRNA in ischemic stroke etiology and pathology.

Authors:  Cameron Rink; Savita Khanna
Journal:  Physiol Genomics       Date:  2010-09-14       Impact factor: 3.107

2.  Six months of aerobic exercise does not improve microvascular function in type 2 diabetes mellitus.

Authors:  A R Middlebrooke; L M Elston; K M Macleod; D M Mawson; C I Ball; A C Shore; J E Tooke
Journal:  Diabetologia       Date:  2006-08-30       Impact factor: 10.122

3.  Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome.

Authors:  Abdul Hye Khan; John D Imig
Journal:  Am J Hypertens       Date:  2011-03-17       Impact factor: 2.689

4.  Chronic insulin treatment amplifies PDGF-induced motility in differentiated aortic smooth muscle cells by suppressing the expression and function of PTP1B.

Authors:  Daming Zhuang; Qinghua Pu; Bogdan Ceacareanu; Yingzi Chang; Madhulika Dixit; Aviv Hassid
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-05-02       Impact factor: 4.733

5.  The Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil Ameliorates Insulin Resistance Induced by Chronic Angiotensin II Treatment in Rat Skeletal Muscle.

Authors:  Guido Lastra; Fernando R Santos; Payam Hooshmand; Paria Hooshmand; Irina Mugerfeld; Annayya R Aroor; Vincent G Demarco; James R Sowers; Erik J Henriksen
Journal:  Cardiorenal Med       Date:  2013-06-25       Impact factor: 2.041

Review 6.  Effect of non-surgical periodontal treatment on glycemic control of patients with diabetes: a meta-analysis of randomized controlled trials.

Authors:  Quan Li; Sha Hao; Jie Fang; Jing Xie; Xiang-Hui Kong; Jian-Xin Yang
Journal:  Trials       Date:  2015-07-03       Impact factor: 2.279

7.  Effects of coenzyme Q10 on cardiovascular and metabolic biomarkers in overweight and obese patients with type 2 diabetes mellitus: a pooled analysis.

Authors:  Haohai Huang; Honggang Chi; Dan Liao; Ying Zou
Journal:  Diabetes Metab Syndr Obes       Date:  2018-11-29       Impact factor: 3.168

Review 8.  The Potential Health Benefits of the Ketogenic Diet: A Narrative Review.

Authors:  Kathryn Dowis; Simran Banga
Journal:  Nutrients       Date:  2021-05-13       Impact factor: 5.717

9.  An Angiotensin II (Ang II) Type 1 Receptor Blocker, Telmisartan, Improves Insulin Resistance in KK-A(y) Diabetic Mice.

Authors:  Toshiyuki Takasu; Hirotoshi Kakuta; Masao Sasamata; Sho-Ichi Yamagishi
Journal:  Int J Biomed Sci       Date:  2006-12

10.  Differentiated miRNA expression and validation of signaling pathways in apoE gene knockout mice by cross-verification microarray platform.

Authors:  Hui Han; Yu-Hong Wang; Guang-Jin Qu; Ting-Ting Sun; Feng-Qing Li; Wei Jiang; Shan-Shun Luo
Journal:  Exp Mol Med       Date:  2013-03-08       Impact factor: 8.718
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.